Antiverse is a leading Generative AI TechBio company specializing in therapeutic antibody design for difficult targets, such as GPCRs, ion channels and other transmembrane proteins.

Starting from only the target sequence or structure, our Generative AI Antibody Discovery platform designs functional antibodies against difficult targets in 6 months. Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to design de novo antibody therapeutics.

Our platform technology is leading the development of nine antibody discovery programmes for challenging targets, three of which are in partnership with the top 20 global pharmaceutical companies.

We are seeking pharma partners with extremely challenging projects, mostly involving transmembrane proteins, such as GPCRs, ion channels, and SLCs. We have the capacity to run several programs in parallel, and we operate with flexible financial and exclusivity terms within the budget and risk parameters of our partner.

How we can work together:

• AI-Powered de novo Biologics Discovery (new programs): Design, test, and select functional biologics for difficult targets such as GPCRs or ion channels in 6 months.
• AI-Augmented Biologics Optimisation: Using existing project-specific data (lead candidates or negative data) to optimise/design biologics with specific properties (function, affinity, specificity, etc.).

Highlights of Antiverse's progress:

• Active programs with 3 top 20 pharma
• Human data on an internal pipeline GPCR program
• In 12 months, designed novel antibodies against 3 GPCRs
• Target/epitope-specific library design
• Increased AI prediction accuracy; 1 binder in 10K predictions
• Scalable platform/work flow: Ability to run several programs in parallel

Non-confidential deck: https://docsend.com/view/bagj3wjj7rt9b33r